198 related articles for article (PubMed ID: 31954377)
1. A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
Chand S; Mahajan RV; Prasad JP; Sahoo DK; Mihooliya KN; Dhar MS; Sharma G
Biotechnol Appl Biochem; 2020 Jul; 67(4):619-647. PubMed ID: 31954377
[TBL] [Abstract][Full Text] [Related]
2. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
3. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
Fernandez CA; Stewart E; Panetta JC; Wilkinson MR; Morrison AR; Finkelman FD; Sandlund JT; Pui CH; Jeha S; Relling MV; Campbell PK
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1307-13. PubMed ID: 24771103
[TBL] [Abstract][Full Text] [Related]
4. Solid-State Fermentation vs Submerged Fermentation for the Production of l-Asparaginase.
Doriya K; Jose N; Gowda M; Kumar DS
Adv Food Nutr Res; 2016; 78():115-35. PubMed ID: 27452168
[TBL] [Abstract][Full Text] [Related]
5. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
6. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Review on L-Asparaginase and Its Applications.
Batool T; Makky EA; Jalal M; Yusoff MM
Appl Biochem Biotechnol; 2016 Mar; 178(5):900-23. PubMed ID: 26547852
[TBL] [Abstract][Full Text] [Related]
8. Current applications and different approaches for microbial l-asparaginase production.
Cachumba JJ; Antunes FA; Peres GF; Brumano LP; Santos JC; Da Silva SS
Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):77-85. PubMed ID: 27866936
[TBL] [Abstract][Full Text] [Related]
9. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
11. Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Asselin BL; Fisher V
Clin J Oncol Nurs; 2014 Dec; 18(6):E107-12. PubMed ID: 25427712
[TBL] [Abstract][Full Text] [Related]
12. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
14. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.
Zalewska-Szewczyk B; Gach A; Wyka K; Bodalski J; Młynarski W
Clin Exp Med; 2009 Jun; 9(2):113-6. PubMed ID: 19184328
[TBL] [Abstract][Full Text] [Related]
15. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Burke MJ
Future Oncol; 2014 Dec; 10(16):2615-27. PubMed ID: 24983955
[TBL] [Abstract][Full Text] [Related]
16. L-asparaginase: a promising chemotherapeutic agent.
Verma N; Kumar K; Kaur G; Anand S
Crit Rev Biotechnol; 2007; 27(1):45-62. PubMed ID: 17364689
[TBL] [Abstract][Full Text] [Related]
17. Recent research progress on microbial L-asparaginases.
Zuo S; Zhang T; Jiang B; Mu W
Appl Microbiol Biotechnol; 2015 Feb; 99(3):1069-79. PubMed ID: 25492420
[TBL] [Abstract][Full Text] [Related]
18. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
20. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Billett AL; Carls A; Gelber RD; Sallan SE
Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
